CAR-T cell therapy for hard-to-treat nerve autoimmune diseases
Part of Brain & nervous system, Cancer, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a universal CAR-T cell treatment for people with autoimmune diseases of the nervous system that haven't responded to standard therapies. It aims to see if this therapy can help control diseases like neuromyelitis optica, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multiple sclerosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old (if you have multiple sclerosis, age 18 to 55).
- You have an autoimmune disease of the nervous system that has not improved with standard treatments or has no effective treatment available.
- You agree to use birth control during the study and for one year after treatment.
- You do not have a history of organ transplant, active cancer, serious infections like HIV or hepatitis, or severe heart disease.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This early-stage trial tests a new type of immune cell therapy (CAR T-cells) against several relapsed or hard-to-treat autoimmune diseases that affect the nervous system. The goal is to see if this treatment can safely calm the immune system and improve symptoms.
This trial tests a treatment called CNCT19, a type of CAR-T cell therapy, for people with certain autoimmune diseases like neuromyelitis optica, myasthenia gravis, or multiple sclerosis that have come back or not responded to other treatments. It aims to see if targeting a specific immune cell (CD19) can help control the disease.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It is for people with certain autoimmune diseases (like lupus or scleroderma) that have not responded well to standard treatments or have relapsed after prior cell therapy.
This trial tests whether CAR-T cells, a type of immune cell therapy, can help people with certain autoimmune diseases. If you have lupus, scleroderma, or other listed conditions, you may be able to join and see if this treatment can calm your overactive immune system.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.